Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function

Ranya Elsayed, Pheba Abraham, Mohamed E. Awad, Zoya Bronislavovna Kurago, Balasudha Baladhandayutham, Gary M. Whitford, David Henry Pashley, Charles E. McKenna, Mohammed Elsayed Elsalanty

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Unlike other antiresorptive medications, bisphosphonate molecules accumulate in the bone matrix. Previous studies of side-effects of anti-resorptive treatment focused mainly on systemic effects. We hypothesize that matrix-bound bisphosphonate molecules contribute to the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). In this study, we examined the effect of matrix-bound bisphosphonates on osteoclast differentiation in vitro using TRAP staining and resorption assay, with and without pretreatment with EDTA. We also tested the effect of zoledronate chelation on the healing of post-extraction defect in rats. Our results confirmed that bisphosphonates bind to, and can be chelated from, mineralized matrix in vitro in a dose-dependent manner. Matrix-bound bisphosphonates impaired the differentiation of osteoclasts, evidenced by TRAP activity and resorption assay. Zoledronate-treated rats that underwent bilateral dental extraction with unilateral EDTA treatment showed significant improvement in mucosal healing and micro-CT analysis on the chelated sides. The results suggest that matrix-bound bisphosphonates are accessible to osteoclasts and chelating agents and contribute to the pathogenesis of BRONJ. The use of topical chelating agents is a promising strategy for the prevention of BRONJ following dental procedures in bisphosphonate-treated patients.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalBone
Volume110
DOIs
StatePublished - May 1 2018

Fingerprint

zoledronic acid
Osteonecrosis
Diphosphonates
Osteoclasts
Jaw
Bisphosphonate-Associated Osteonecrosis of the Jaw
Chelating Agents
Edetic Acid
Tooth Extraction
Bone Matrix
Tooth

Keywords

  • Alveolar bone
  • Bisphosphonates
  • Bone matrix
  • Chelating agents
  • Osteonecrosis
  • Osteoporosis treatment
  • Zoledronate

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. / Elsayed, Ranya; Abraham, Pheba; Awad, Mohamed E.; Kurago, Zoya Bronislavovna; Baladhandayutham, Balasudha; Whitford, Gary M.; Pashley, David Henry; McKenna, Charles E.; Elsalanty, Mohammed Elsayed.

In: Bone, Vol. 110, 01.05.2018, p. 141-149.

Research output: Contribution to journalArticle

Elsayed, Ranya ; Abraham, Pheba ; Awad, Mohamed E. ; Kurago, Zoya Bronislavovna ; Baladhandayutham, Balasudha ; Whitford, Gary M. ; Pashley, David Henry ; McKenna, Charles E. ; Elsalanty, Mohammed Elsayed. / Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. In: Bone. 2018 ; Vol. 110. pp. 141-149.
@article{091fadebeeae47918a76a29ae7fa6a74,
title = "Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function",
abstract = "Unlike other antiresorptive medications, bisphosphonate molecules accumulate in the bone matrix. Previous studies of side-effects of anti-resorptive treatment focused mainly on systemic effects. We hypothesize that matrix-bound bisphosphonate molecules contribute to the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). In this study, we examined the effect of matrix-bound bisphosphonates on osteoclast differentiation in vitro using TRAP staining and resorption assay, with and without pretreatment with EDTA. We also tested the effect of zoledronate chelation on the healing of post-extraction defect in rats. Our results confirmed that bisphosphonates bind to, and can be chelated from, mineralized matrix in vitro in a dose-dependent manner. Matrix-bound bisphosphonates impaired the differentiation of osteoclasts, evidenced by TRAP activity and resorption assay. Zoledronate-treated rats that underwent bilateral dental extraction with unilateral EDTA treatment showed significant improvement in mucosal healing and micro-CT analysis on the chelated sides. The results suggest that matrix-bound bisphosphonates are accessible to osteoclasts and chelating agents and contribute to the pathogenesis of BRONJ. The use of topical chelating agents is a promising strategy for the prevention of BRONJ following dental procedures in bisphosphonate-treated patients.",
keywords = "Alveolar bone, Bisphosphonates, Bone matrix, Chelating agents, Osteonecrosis, Osteoporosis treatment, Zoledronate",
author = "Ranya Elsayed and Pheba Abraham and Awad, {Mohamed E.} and Kurago, {Zoya Bronislavovna} and Balasudha Baladhandayutham and Whitford, {Gary M.} and Pashley, {David Henry} and McKenna, {Charles E.} and Elsalanty, {Mohammed Elsayed}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.bone.2018.01.030",
language = "English (US)",
volume = "110",
pages = "141--149",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function

AU - Elsayed, Ranya

AU - Abraham, Pheba

AU - Awad, Mohamed E.

AU - Kurago, Zoya Bronislavovna

AU - Baladhandayutham, Balasudha

AU - Whitford, Gary M.

AU - Pashley, David Henry

AU - McKenna, Charles E.

AU - Elsalanty, Mohammed Elsayed

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Unlike other antiresorptive medications, bisphosphonate molecules accumulate in the bone matrix. Previous studies of side-effects of anti-resorptive treatment focused mainly on systemic effects. We hypothesize that matrix-bound bisphosphonate molecules contribute to the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). In this study, we examined the effect of matrix-bound bisphosphonates on osteoclast differentiation in vitro using TRAP staining and resorption assay, with and without pretreatment with EDTA. We also tested the effect of zoledronate chelation on the healing of post-extraction defect in rats. Our results confirmed that bisphosphonates bind to, and can be chelated from, mineralized matrix in vitro in a dose-dependent manner. Matrix-bound bisphosphonates impaired the differentiation of osteoclasts, evidenced by TRAP activity and resorption assay. Zoledronate-treated rats that underwent bilateral dental extraction with unilateral EDTA treatment showed significant improvement in mucosal healing and micro-CT analysis on the chelated sides. The results suggest that matrix-bound bisphosphonates are accessible to osteoclasts and chelating agents and contribute to the pathogenesis of BRONJ. The use of topical chelating agents is a promising strategy for the prevention of BRONJ following dental procedures in bisphosphonate-treated patients.

AB - Unlike other antiresorptive medications, bisphosphonate molecules accumulate in the bone matrix. Previous studies of side-effects of anti-resorptive treatment focused mainly on systemic effects. We hypothesize that matrix-bound bisphosphonate molecules contribute to the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). In this study, we examined the effect of matrix-bound bisphosphonates on osteoclast differentiation in vitro using TRAP staining and resorption assay, with and without pretreatment with EDTA. We also tested the effect of zoledronate chelation on the healing of post-extraction defect in rats. Our results confirmed that bisphosphonates bind to, and can be chelated from, mineralized matrix in vitro in a dose-dependent manner. Matrix-bound bisphosphonates impaired the differentiation of osteoclasts, evidenced by TRAP activity and resorption assay. Zoledronate-treated rats that underwent bilateral dental extraction with unilateral EDTA treatment showed significant improvement in mucosal healing and micro-CT analysis on the chelated sides. The results suggest that matrix-bound bisphosphonates are accessible to osteoclasts and chelating agents and contribute to the pathogenesis of BRONJ. The use of topical chelating agents is a promising strategy for the prevention of BRONJ following dental procedures in bisphosphonate-treated patients.

KW - Alveolar bone

KW - Bisphosphonates

KW - Bone matrix

KW - Chelating agents

KW - Osteonecrosis

KW - Osteoporosis treatment

KW - Zoledronate

UR - http://www.scopus.com/inward/record.url?scp=85041499490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041499490&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2018.01.030

DO - 10.1016/j.bone.2018.01.030

M3 - Article

VL - 110

SP - 141

EP - 149

JO - Bone

JF - Bone

SN - 8756-3282

ER -